NLRP3 and lung cancer: Expectedly, in the present study, we found that BFXJY treatment relieved the up-regulation of NLRP3 inflammasome responses in lung cancer with Qi-yin deficiency, as indicated by the decrease of the serum, mRNA, and protein level of NLRP3, ASC, IL-1β, MDA.